POZEN Announces Receipt Of Three Patents From The United States Patent And Trademark Office

POZEN Inc.

, a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has received three patents from the United States Patent and Trademark Office (USPTO), entitled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” that cover the U.S. approved product VIMOVO® (naproxen / esomeprazole magnesium) delayed-release tablets. “These newly issued patents provide additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “Additionally, these patents demonstrate the continued pattern of innovation by POZEN, which has resulted in 16 issued U.S. Patents and many related foreign patents.” The USPTO issued U.S. Patent numbers 8,865,190 on October 21, 2014, 8,858,996 on October 14, 2014 and 8,852,636 on October 7, 2014. All three patents are expected to expire in 2022. Horizon Pharma plc

, which holds the U.S. NDA for VIMOVO, and POZEN plan to list U.S. patents 8,858,996 and 8,852,636 in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will bring to ten, the total patents listed in the Orange Book for VIMOVO. U.S. patent 8,865,190, which covers the process for preparing VIMOVO, is not eligible to be listed in the Orange Book.